0001100682-20-000012 | 10-Q | XBRL Viewer | Charles River Laboratories International INC

Print Document View Excel Document

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 28, 2020	Apr. 24, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 28, 2020
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,487,437
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-26
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Total revenue	$ 707,059	$ 604,569
Costs and expenses:
Selling, general and administrative	129,901	122,574
Amortization of intangible assets	27,879	19,411
Operating income	94,281	69,792
Other income (expense):
Interest income	316	179
Interest expense	(15,067)	(9,987)
Other (expense) income, net	(24,071)	6,306
Income from operations, before income taxes	55,459	66,290
Provision for income taxes	4,622	10,602
Net income	50,837	55,688
Less: Net income attributable to noncontrolling interests	68	555
Net income attributable to common shareholders	$ 50,769	$ 55,133
Earnings per common share
Basic (in dollars per share)	$ 1.03	$ 1.14
Diluted (in dollars per share)	$ 1.02	$ 1.11
Weighted-average number of common shares outstanding:
Basic (in shares)	49,189	48,458
Diluted (in shares)	49,966	49,462
Service
Total revenue	$ 546,592	$ 450,942
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	372,824	316,800
Product
Total revenue	160,467	153,627
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	$ 82,174	$ 75,992

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 50,837	$ 55,688
Other comprehensive income (loss):
Foreign currency translation adjustment and other	(44,855)	9,885
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	1,374	374
Comprehensive income, before income taxes	7,356	65,947
Less: Income tax benefit related to items of other comprehensive income	(2,039)	(102)
Comprehensive income, net of income taxes	9,395	66,049
Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes	(476)	1,013
Comprehensive income attributable to common shareholders, net of income taxes	$ 9,871	$ 65,036

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Current assets:
Cash and cash equivalents	$ 372,433	$ 238,014
Trade receivables, net	542,390	514,033
Inventories	162,938	160,660
Prepaid assets	68,826	52,588
Other current assets	61,694	56,030
Total current assets	1,208,281	1,021,325
Property, plant and equipment, net	1,033,409	1,044,128
Operating lease right-of-use assets, net	155,568	140,085
Goodwill	1,731,837	1,540,565
Client relationships and other intangible assets, net	832,863	689,413
Deferred tax assets	42,753	44,659
Other assets	197,079	212,615
Total assets	5,201,790	4,692,790
Current liabilities:
Current portion of long-term debt and finance leases	47,667	38,545
Accounts payable	102,697	111,498
Accrued compensation	113,620	158,617
Deferred revenue	178,829	171,805
Accrued liabilities	139,163	139,118
Other current liabilities	108,920	90,598
Total current liabilities	690,896	710,181
Long-term debt, net and finance leases	2,326,770	1,849,666
Operating lease right-of-use liabilities	133,440	116,252
Deferred tax liabilities	197,094	167,283
Other long-term liabilities	173,924	182,933
Total liabilities	3,522,124	3,026,315
Commitments and contingencies (Notes 2, 9, 11, 12, 16 and 17)
Redeemable noncontrolling interests	24,039	28,647
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 49,630 shares issued and 49,486 shares outstanding as of March 28, 2020, and 48,936 shares issued and 48,936 shares outstanding as of December 28, 2019	496	489
Additional paid-in capital	1,562,982	1,531,785
Retained earnings	331,098	280,329
Treasury stock, at cost, 144 and 0 shares, as of March 28, 2020 and December 28, 2019, respectively	(23,675)	0
Accumulated other comprehensive loss	(218,917)	(178,019)
Total equity attributable to common shareholders	1,651,984	1,634,584
Noncontrolling interest	3,643	3,244
Total equity	1,655,627	1,637,828
Total liabilities, redeemable noncontrolling interests and equity	5,201,790	4,692,790
Client relationships, net
Current assets:
Client relationships and other intangible assets, net	752,516	613,573
Other intangible assets, net
Current assets:
Client relationships and other intangible assets, net	$ 80,347	$ 75,840

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 28, 2020	Dec. 28, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	49,630,000	48,936,000
Common stock, shares outstanding (in shares)	49,486,000	48,936,000
Treasury stock, shares (in shares)	144,000	0

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Cash flows relating to operating activities
Net income	$ 50,837	$ 55,688
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	57,260	45,358
Stock-based compensation	10,960	12,899
Deferred income taxes	(2,973)	7,781
Loss (gain) on venture capital and other investments	12,035	(10,575)
Other, net	10,495	(380)
Changes in assets and liabilities:
Trade receivables, net	(32,136)	(23,127)
Inventories	4,076	(2,520)
Accounts payable	(10,003)	10,245
Accrued compensation	(45,245)	(55,114)
Deferred revenue	6,065	(14,405)
Customer contract deposits	4,454	(5,866)
Other assets and liabilities, net	2,765	(5,125)
Net cash provided by operating activities	68,590	14,859
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(382,250)	(989)
Capital expenditures	(25,721)	(16,731)
Purchases of investments and contributions to venture capital investments	(7,121)	(2,419)
Proceeds from sale of investments	2,504	15
Other, net	(1,097)	(689)
Net cash used in investing activities	(413,685)	(20,813)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	1,409,793	290,111
Proceeds from exercises of stock options	22,608	21,832
Payments on long-term debt, revolving credit facility, and finance lease obligations	(925,109)	(360,658)
Purchase of treasury stock	(23,675)	(17,760)
Other, net	(4,405)	(2,608)
Net cash provided by (used in) financing activities	479,212	(69,083)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	290	6,025
Net change in cash, cash equivalents, and restricted cash	134,407	(69,012)
Cash, cash equivalents, and restricted cash, beginning of period	240,046	197,318
Cash, cash equivalents, and restricted cash, end of period	374,453	128,306
Supplemental cash flow information:
Cash, cash equivalents, and restricted cash, end of period	$ 374,453	$ 128,306

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Equity Attributable to Common Shareholders	Noncontrolling Interest
Beginning balance (in shares) at Dec. 29, 2018		48,210				1
Beginning balance at Dec. 29, 2018	$ 1,319,778	$ 482	$ 1,447,512	$ 42,096	$ (172,703)	$ (55)	$ 1,317,332	$ 2,446
Increase (Decrease) in Stockholders' Equity
Net income	55,602			55,133			55,133	469
Other comprehensive income (loss)	9,903				9,903		9,903
Adjustment of redeemable noncontrolling interest to redemption value	(1,451)		(1,451)				(1,451)
Issuance of stock under employee compensation plans (in shares)		674
Issuance of stock under employee compensation plans	22,058	$ 7	22,051				22,058
Acquisition of treasury shares (in shares)						136
Acquisition of treasury shares	(17,760)					$ (17,760)	(17,760)
Stock-based compensation	12,899		12,899				12,899
Ending balance (in shares) at Mar. 30, 2019		48,884				137
Ending balance at Mar. 30, 2019	1,401,029	$ 489	1,481,011	97,229	(162,800)	$ (17,815)	1,398,114	2,915
Beginning balance (in shares) at Dec. 28, 2019		48,936				0
Beginning balance at Dec. 28, 2019	1,637,828	$ 489	1,531,785	280,329	(178,019)	$ 0	1,634,584	3,244
Increase (Decrease) in Stockholders' Equity
Net income	51,168			50,769			50,769	399
Other comprehensive income (loss)	(40,898)				(40,898)		(40,898)
Buy-out and contingent consideration recognition in connection with redeemable noncontrolling interest	(2,379)		(2,379)				(2,379)
Issuance of stock under employee compensation plans (in shares)		694
Issuance of stock under employee compensation plans	22,623	$ 7	22,616				22,623
Acquisition of treasury shares (in shares)						144
Acquisition of treasury shares	(23,675)					$ (23,675)	(23,675)
Stock-based compensation	10,960		10,960				10,960
Ending balance (in shares) at Mar. 28, 2020		49,630				144
Ending balance at Mar. 28, 2020	$ 1,655,627	$ 496	$ 1,562,982	$ 331,098	$ (218,917)	$ (23,675)	$ 1,651,984	$ 3,643

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2019. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The COVID-19 pandemic is dynamic and expanding, and its ultimate scope, duration and effects are uncertain. This pandemic has and continues to result in, and any future epidemic or pandemic crises may potentially result in, direct and indirect adverse effects on the Company’s industry and customers, which in turn has (with respect to COVID-19) and may (with respect to future epidemics or crises) impact the Company’s business, results of operations and financial condition. Further, the COVID-19 pandemic may also affect the Company’s operating and financial results in a manner that is not presently known to the Company or that the Company currently does not expect to present significant risks to its operations or financial results. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research Products businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services). Research Products supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Testing Services (Biologics), which performs specialized testing of biologics; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2019. Newly Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (FASB) issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computer Arrangement that is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes the disclosure requirement for the amount and reasons for transfers between Level 1 and Level 2 fair value measurements as well as the process for Level 3 fair value measurements. In addition, the ASU adds the disclosure requirements for changes in unrealized gains and losses included in Other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period as well as the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20).” ASU 2018-14 removes the requirements to disclose the amounts in Accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and the related party disclosures about the amount of future annual benefits covered by insurance contracts. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. This standard became effective for the Company in the three months ended March 28, 2020 and did not have an impact on the unaudited condensed consolidated financial statements and related disclosures. The Company performs its annual impairment test during the fourth quarter of a fiscal year and does not expect any significant impact on the consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses”. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as trade and notes receivables, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU offers temporary optional expedients and exceptions for applying U.S. GAAP to modifications to agreements such as loans, debt securities, derivatives, and borrowings which reference LIBOR or another reference rate that is expected to be discontinued by December 31, 2021. The expedients and exceptions provided by the standard do not apply to modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for hedging relationships existing as of December 31, 2022 that an entity has elected certain optional expedients for and are retained through the end of the hedging relationship. The ASU is effective until December 31, 2022 when the replacement for LIBOR is expected to be completed. The interest rate on the Company’s senior credit facility, which matures in fiscal year 2023, is linked to LIBOR. The Company is in the process of evaluating options for transitioning away from the senior credit facility’s use of LIBOR and expects to be completed by the time LIBOR is phased out. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures and has yet to elect an adoption date. In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied either retrospectively or prospectively based upon the applicable amendments. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.

BUSINESS ACQUISITIONS

3 Months Ended

Mar. 28, 2020

Business Combinations [Abstract]

BUSINESS ACQUISITIONS

BUSINESS COMBINATIONS

HemaCare Corporation

On January 3, 2020, the Company acquired HemaCare Corporation (HemaCare), a business specializing in the production of human-derived cellular products for the cell therapy market. The acquisition of HemaCare expands the Company’s comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human derived cellular products to better support clients’ cell therapy programs. The purchase price of HemaCare was $379.8 million in cash. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s Credit Facility under the multi-currency revolving facility. See Note 9, “Long-Term Debt and Finance Leases.” This business is reported as part of the Company’s RMS reportable segment.

The preliminary purchase allocation of $376.7 million, net of $3.1 million of cash acquired was as follows:


	January 3, 2020
	(in thousands)
Trade receivables	$	6,451
Inventories	8,468
Other current assets (excluding cash)	3,527
Property, plant and equipment	10,033
Goodwill	209,104
Definite-lived intangible assets	183,540
Other long-term assets	5,920
Current liabilities	(5,188)
Deferred tax liabilities	(37,470)
Other long-term liabilities	(7,664)
Total purchase price allocation	$	376,721

The breakout of definite-lived intangible assets acquired was as follows:


	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	170,390	19
Trade name	7,330		10
Other intangible assets	5,820		3
Total definite-lived intangible assets	$	183,540	18

The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s RMS business from customers introduced through HemaCare and the assembled workforce of the acquired business. The goodwill attributable to HemaCare is not deductible for tax purposes.

The Company incurred transaction and integration costs in connection with the acquisition of $5.7 million for the three months ended March 28, 2020, which were primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

Beginning on January 3, 2020, HemaCare has been included in the operating results of the Company. HemaCare revenue and operating loss for the three months ended March 28, 2020 was $12.3 million and $2.2 million, respectively.

The following selected unaudited pro forma consolidated results of operations are presented as if the HemaCare acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 30, 2018, after giving effect to certain adjustments. For the three months ended March 28, 2020, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $0.2 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. For the three months ended March 30, 2019, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $3.2 million, additional interest expense on borrowings of $2.8 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
	(unaudited)
Revenue	$	707,077	$	613,456
Net income attributable to common shareholders	55,705		52,186

These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition.

Citoxlab

On April 29, 2019, the Company acquired Citoxlab, a non-clinical CRO, specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab further strengthens the Company’s position as a leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which enhances the Company’s ability to partner with clients across the drug discovery and development continuum. The purchase price for Citoxlab was $527.1 million in cash. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s Credit Facility under the multi-currency revolving facility. This business is reported as part of the Company’s DSA reportable segment.

The purchase allocation of $490.4 million, net of $36.7 million of cash acquired was as follows:


	April 29, 2019
	(in thousands)
Trade receivables	$	35,405
Inventories	5,282
Other current assets (excluding cash)	13,917
Property, plant and equipment	88,605
Goodwill	280,161
Definite-lived intangible assets	162,400
Other long-term assets	20,063
Deferred revenue	(15,278)
Current liabilities	(46,081)
Deferred tax liabilities	(27,458)
Other long-term liabilities	(22,624)
Redeemable noncontrolling interest	(4,035)
Total purchase price allocation	$	490,357

From the date of the acquisition through March 28, 2020, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation.

The breakout of definite-lived intangible assets acquired was as follows:


	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	134,600	13
Developed technology	19,900		3
Backlog	7,900		1
Total definite-lived intangible assets	$	162,400	12

The goodwill resulting from the transaction, $7.2 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through Citoxlab and the assembled workforce of the acquired business.

The Company incurred transaction and integration costs in connection with the acquisition of $1.4 million and $5.2 million for the three months ended March 28, 2020 and March 30, 2019, respectively, which were primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

Beginning on April 29, 2019, Citoxlab has been included in the operating results of the Company. Citoxlab revenue and operating income for the three months ended March 28, 2020 was $45.3 million and $2.5 million, respectively.

The following selected unaudited pro forma consolidated results of operations are presented as if the Citoxlab acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 31, 2017, after giving effect to certain adjustments. For the three months ended March 30, 2019, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $2.6 million, additional interest expense on borrowings of $1.2 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.

Three Months Ended

March 30, 2019

(in thousands)

(unaudited)

Revenue

650,875

Net income attributable to common shareholders

61,028

Other Acquisition

On August 28, 2019, the Company acquired an 80% ownership interest in a supplier that supports the Company’s DSA reportable segment. The remaining 20% interest is a redeemable non-controlling interest. See Note 10, “Equity and Noncontrolling Interests.” The purchase price was $23.4 million, net of a $4.0 million pre-existing relationship for a supply agreement settled upon acquisition. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s Credit Facility under the multi-currency revolving facility. The business is reported as part of the Company’s DSA reportable segment.

The purchase allocation of $23.1 million, net of $0.3 million of cash acquired was as follows:


	August 28, 2019
	(in thousands)
Trade receivables	$	189
Inventories	7,644
Property, plant and equipment	1,462
Goodwill	12,669
Other long-term assets	11,849
Current liabilities	(441)
Deferred tax liabilities	(1,331)
Other long-term liabilities	(238)
Redeemable noncontrolling interest	(8,740)
Total purchase price allocation	$	23,063

The purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. From the date of the acquisition through March 28, 2020, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis.

No significant integration costs were incurred with the acquisition for the three months ended March 28, 2020.

Pro forma financial information as well as the disclosure of actual results have not been included because these financial results are not significant when compared to the Company’s consolidated financial results.

REVENUE FROM CONTRACTS WITH CUSTOMERS

3 Months Ended

Mar. 28, 2020

Revenue from Contract with Customer [Abstract]

REVENUE FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Major Products/Service Lines:
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	60,041	$	54,813
Services and products transferred at a point in time	85,955		82,359
DSA
Services and products transferred over time	438,564		354,078
Services and products transferred at a point in time	119		119
Manufacturing
Services and products transferred over time	37,314		31,896
Services and products transferred at a point in time	85,066		81,304
Total revenue	$	707,059	$	604,569

RMS

The RMS business generates revenue through the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models and products is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date.

DSA

The Discovery and Safety Assessment business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. Discovery and Safety Assessment services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively.

Manufacturing

The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Testing Services (Biologics), which performs specialized testing of biologics; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract.

Transaction Price Allocated to Future Performance Obligations

The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 28, 2020. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed. The Company has assessed future performance obligations with respect to the COVID-19 pandemic uncertainties and believes there is an insignificant impact on the ability to meet future performance obligations and the amount of revenue to be recognized.

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 28, 2020:


	Revenue Expected to be Recognized in Future Periods
	Less than 1 Year		1 to 3 Years		4 to 5 Years		Beyond 5 Years		Total
	(in thousands)
DSA	$	195,192	$	92,180	$	4,861	$	639	$	292,872
Manufacturing	10,241		8,825		32		21		19,119
Total	$	205,433	$	101,005	$	4,893	$	660	$	311,991

Contract Balances from Contracts with Customers

The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the unaudited condensed consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:


	March 28, 2020		December 28, 2019
	(in thousands)
Balances from contracts with customers:
Client receivables	$	415,359	$	395,740
Contract assets (unbilled revenue)	131,660		121,957
Contract liabilities (current and long-term deferred revenue)	194,907		192,788
Contract liabilities (customer contract deposits)	37,319		33,080

When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $19 million and $27 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of March 28, 2020 and December 28, 2019, respectively. Advanced client payments of approximately $37 million and $33 million have been presented as customer contract deposits within other current liabilities in the accompanying unaudited condensed consolidated balance sheets as of March 28, 2020 and December 28, 2019, respectively.

Other changes in the contract asset and the contract liability balances during the three months ended March 28, 2020 were as follows:

(i) Changes due to business combinations:

See Note 2. “Business Combinations” for client receivables, contract assets, and contract liabilities that were acquired as part of the HemaCare acquisition on January 3, 2020.

(ii) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification:

During the three months ended March 28, 2020, an immaterial cumulative catch-up adjustment to revenue was recorded.

(iii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable):

Approximately 60% of unbilled revenue as of December 28, 2019 was billed during the three months ended March 28, 2020.

(iv) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability):

Approximately 60% of contract liabilities as of December 28, 2019 were recognized as revenue during the three months ended March 28, 2020.

SEGMENT INFORMATION

3 Months Ended

Mar. 28, 2020

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company’s three reportable segments are RMS, DSA, and Manufacturing. The following table presents revenue and other financial information by reportable segment:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
RMS
Revenue	$	145,996	$	137,172
Operating income	27,373		37,832
Depreciation and amortization	8,752		4,322
Capital expenditures	5,412		4,112
DSA
Revenue	$	438,683	$	354,197
Operating income	72,283		46,705
Depreciation and amortization	41,330		33,784
Capital expenditures	14,729		8,848
Manufacturing
Revenue	$	122,380	$	113,200
Operating income	41,112		31,499
Depreciation and amortization	6,366		5,805
Capital expenditures	5,161		3,606

Reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows:


	Operating Income						Depreciation and Amortization						Capital Expenditures
	March 28, 2020		March 30, 2019		March 28, 2020		March 30, 2019		March 28, 2020		March 30, 2019
	(in thousands)
Three Months Ended:
Total reportable segments	$	140,768	$	116,036	$	56,448	$	43,911	$	25,302	$	16,566
Unallocated corporate	(46,487)		(46,244)		812		1,447		419		165
Total consolidated	$	94,281	$	69,792	$	57,260	$	45,358	$	25,721	$	16,731

Revenue for each significant product or service offering is as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569

A summary of unallocated corporate expense consists of the following:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Stock-based compensation	$	6,704	$	8,274
Compensation, benefits, and other employee-related expenses	21,980		22,038
External consulting and other service expenses	2,469		3,810
Information technology	3,716		2,723
Depreciation	812		1,447
Acquisition and integration	6,983		5,472
Other general unallocated corporate	3,823		2,480
Total unallocated corporate expense	$	46,487	$	46,244

Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

Revenue by geographic area is as follows:


	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 28, 2020	$	406,712	$	190,262	$	76,633	$	31,829	$	1,623	$	707,059
March 30, 2019	350,176		166,365		53,979		33,179		870		604,569

Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area.

SUPPLEMENTAL BALANCE SHEET INFORMATION

3 Months Ended

Mar. 28, 2020

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

The composition of trade receivables, net is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Client receivables	$	415,359	$	395,740
Unbilled revenue	131,660		121,957
Total	547,019		517,697
Less: Allowance for doubtful accounts	(4,629)		(3,664)
Trade receivables, net	$	542,390	$	514,033

The composition of inventories is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Raw materials and supplies	$	24,708	$	24,613
Work in process	30,418		35,852
Finished products	107,812		100,195
Inventories	$	162,938	$	160,660

The composition of other current assets is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Prepaid income tax	$	60,016	$	54,358
Short-term investments	934		941
Restricted cash	444		431
Other	300		300
Other current assets	$	61,694	$	56,030

The composition of other assets is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Venture capital investments	$	98,405	$	108,983
Other investments	18,659		13,996
Life insurance policies	31,617		38,207
Other long-term income tax assets	20,534		20,570
Restricted cash	1,576		1,601
Other	26,288		29,258
Other assets	$	197,079	$	212,615

The composition of other current liabilities is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Current portion of operating lease right-of-use liabilities	$	22,469	$	20,357
Accrued income taxes	25,706		26,066
Customer contract deposits	37,319		33,080
Other	23,426		11,095
Other current liabilities	$	108,920	$	90,598

The composition of other long-term liabilities is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
U.S. Transition Tax	$	50,057	$	52,066
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan	78,272		80,833
Long-term deferred revenue	16,078		20,983
Other	29,517		29,051
Other long-term liabilities	$	173,924	$	182,933

VENTURE CAPITAL AND OTHER INVESTMENTS	3 Months Ended
VENTURE CAPITAL AND OTHER INVESTMENTS	Mar. 28, 2020
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL AND OTHER INVESTMENTS	VENTURE CAPITAL AND OTHER INVESTMENTSVenture capital investments were $98.4 million and $109.0 million as of March 28, 2020 and December 28, 2019, respectively. The Company’s total commitment to the venture capital funds as of March 28, 2020 was $128.4 million, of which the Company funded $82.9 million through that date. The Company received dividends totaling $0.9 million and $0.8 million for the three months ended March 28, 2020 and March 30, 2019, respectively. The Company recognized losses of $12.2 million and gains of $10.6 million related to the venture capital investments for the three months ended March 28, 2020 and March 30, 2019, respectively. The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Other investments were $18.7 million and $14.0 million as of March 28, 2020 and December 28, 2019, respectively. The Company recognized an insignificant amount of gains and losses related to these investments for the three months ended March 28, 2020 and March 30, 2019.

FAIR VALUE

3 Months Ended

Mar. 28, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE

The Company has certain assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy:

•Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,

•Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates,

•Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the three months ended March 28, 2020 and March 30, 2019, there were no transfers between levels.

Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:

•Cash equivalents - Valued at market prices determined through third-party pricing services;

•Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;

•Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;

•Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book value of the Company’s 5.5% Senior Notes due in 2026 and the 4.25% Senior Notes due in 2028 (Senior Notes), which are fixed rate debt, are carried at amortized cost. Fair value of the Senior Notes is based on quoted market prices and on borrowing rates available to the Company; and

•Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes.

Assets and liabilities measured at fair value on a recurring basis are summarized below:


	March 28, 2020
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	186,599	$	—	$	186,599
Other assets:
Life insurance policies	—		23,834		—		23,834
Total assets measured at fair value	$	—	$	210,433	$	—	$	210,433

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	2,563	$	2,563
Total liabilities measured at fair value	$	—	$	—	$	2,563	$	2,563


	December 28, 2019
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	55,278	$	—	$	55,278
Other assets:
Life insurance policies	—		30,454		—		30,454
Total assets measured at fair value	$	—	$	85,732	$	—	$	85,732

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	712	$	712
Foreign currency forward contract	—		876		—		876
Total liabilities measured at fair value	$	—	$	876	$	712	$	1,588

Contingent Consideration

The following table provides a rollforward of the contingent consideration related to previous business acquisitions. See Note 2, “Business Combinations.”


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	712	$	3,033
Additions	2,131		2,000
Payments	(218)		(2,610)
Foreign currency	(62)		74
Ending balance	$	2,563	$	2,497

The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Increases or decreases in any of the probabilities of success would result in a higher or lower fair value measurement, respectively. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.

Debt Instruments

The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.

The book value of the Company’s 2026 and 2028 Senior Notes is a fixed rate obligation carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s 2026 and 2028 Senior Notes is summarized below:


	March 28, 2020						December 28, 2019
	Book Value		Fair Value		Book Value		Fair Value
2026 Senior Notes	$	500,000	$	508,050	$	500,000	$	537,500
2028 Senior Notes	500,000		475,000		500,000		510,000

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 28, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table provides a rollforward of the Company’s goodwill:


			Adjustments to Goodwill
	December 28, 2019		Acquisitions		Foreign Exchange		March 28, 2020
	(in thousands)
RMS	$	56,586	$	209,104	$	(219)	$	265,471
DSA	1,345,223		(550)		(13,865)		1,330,808
Manufacturing	138,756		—		(3,198)		135,558
Goodwill	$	1,540,565	$	208,554	$	(17,282)	$	1,731,837

The increase in goodwill during the three months ended March 28, 2020 related primarily to the acquisition of HemaCare in the RMS reportable segment, which was partially offset by the impact of foreign exchange.

Intangible Assets, Net

The following table displays intangible assets, net by major class:


	March 28, 2020										December 28, 2019
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
	(in thousands)
Backlog	$	28,558	$	(27,133)	$	1,425	$	28,865	$	(26,895)	$	1,970
Technology	123,647		(62,307)		61,340		122,106		(57,737)		64,369
Trademarks and trade names	15,504		(4,983)		10,521		8,430		(4,901)		3,529
Other	19,874		(12,813)		7,061		18,279		(12,307)		5,972
Other intangible assets	187,583		(107,236)		80,347		177,680		(101,840)		75,840
Client relationships	1,085,540		(333,024)		752,516		934,668		(321,095)		613,573
Intangible assets	$	1,273,123	$	(440,260)	$	832,863	$	1,112,348	$	(422,935)	$	689,413

The increase in intangible assets, net during the three months ended March 28, 2020 related primarily to the acquisition of HemaCare.

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS

3 Months Ended

Mar. 28, 2020

Debt Disclosure [Abstract]

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS

Long-term debt, net and finance leases consists of the following:


	March 28, 2020		December 28, 2019
	(in thousands)
Term loans	$	184,375	$	193,750
Revolving facility	1,168,096		676,134
2026 Senior Notes	500,000		500,000
2028 Senior Notes	500,000		500,000
Other debt	10,227		5,781
Finance leases (Note 16)	28,808		30,527
Total debt and finance leases	2,391,506		1,906,192
Less:
Current portion of long-term debt	44,738		35,548
Current portion of finance leases (Note 16)	2,929		2,997
Current portion of long-term debt and finance leases	47,667		38,545
Long-term debt and finance leases	2,343,839		1,867,647
Debt discount and debt issuance costs	(17,069)		(17,981)
Long-term debt, net and finance leases	$	2,326,770	$	1,849,666

As of March 28, 2020 and December 28, 2019, the weighted average interest rate on the Company’s debt was 3.03% and 3.46%, respectively.

Term Loans and Revolving Facility

The Company has a $2.8 billion credit facility (Credit Facility), consisting of a $750 million term loan and a $2.05 billion multi-currency revolving facility. The term loan facility matures in 19 quarterly installments with the last installment due March 26, 2023. On October 23, 2019, the Company prepaid $500.0 million of the term loan with proceeds from a $500.0 million unregistered private offering (see 2028 Senior Notes Offering below). The revolving facility matures on March 26, 2023, and requires no scheduled payment before that date.

Under specified circumstances, the Company has the ability to increase the term loan and/or revolving facility by up to $1.0 billion in the aggregate.

The interest rates applicable to the term loan and revolving facility under the Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1.0%) or the adjusted LIBOR rate, plus an interest rate margin based upon the Company’s leverage ratio.

The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.00 to 1.0. As of March 28, 2020, the Company was compliant with all covenants.

The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company.

During the three months ended March 28, 2020 and March 30, 2019, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility, which ranged from $300 million to $400 million. This resulted in foreign currency losses recognized in Other income, net of $4.2 million and $6.4 million during the three months ended March 28, 2020 and March 30, 2019, respectively, related to the remeasurement of the underlying debt. The Company entered into foreign exchange forward contracts to limit its foreign currency exposures related to these borrowings and recognized gains of $6.1 million and $8.9 million during the three months ended March 28, 2020 and March 30, 2019, respectively, within Interest expense. As of March 28, 2020, the Company did not have any outstanding borrowings in a currency different than its respective functional currency. See Note 14, “Foreign Currency Contracts”, for further discussion.

Base Indenture for Senior Notes

The Company has an indenture (Base Indenture) with MUFG Union Bank, N.A., (Trustee). The purpose of the Indenture was to allow the Company the ability to issue senior notes. The Company has entered into two supplemental indentures in connection with the senior notes described below.

2026 Senior Notes

In fiscal year 2018, the Company entered into the first supplemental indenture (First Supplemental Indenture) with the Trustee in connection with an offering of $500 million in aggregate principal amount of the Company’s 5.5% Senior Notes (2026 Senior Notes), due in 2026, in an unregistered offering. Under the terms of the First Supplemental Indenture, interest on the Senior Notes is payable semi-annually on April 1 and October 1, beginning on October 1, 2018.

2028 Senior Notes

In fiscal year 2019, the Company entered into a second supplemental indenture (Second Supplemental Indenture) with the Trustee in connection with the offering of $500 million in aggregate principal amount of the Company’s 4.25% Senior Notes (2028 Senior Notes), due in 2028, in an unregistered offering. Under the terms of the Second Supplemental Indenture, interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1, beginning on May 1, 2020.

Letters of Credit

As of March 28, 2020 and December 28, 2019, the Company had $8.3 million and $7.5 million, respectively, in outstanding letters of credit.

EQUITY AND NONCONTROLLING INTERESTS

3 Months Ended

Mar. 28, 2020

Equity [Abstract]

EQUITY AND NONCONTROLLING INTERESTS

Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Numerator:
Net income	$	50,837	$	55,688
Less: Net income attributable to noncontrolling interests	68		555
Net income attributable to common shareholders	$	50,769	$	55,133

Denominator:
Weighted-average shares outstanding - Basic	49,189		48,458
Effect of dilutive securities:
Stock options, restricted stock units and performance share units	777		1,004
Weighted-average shares outstanding - Diluted	49,966		49,462

Options to purchase 0.4 million shares for each of the three months ended March 28, 2020 and March 30, 2019, as well as an insignificant number of restricted stock units (RSUs) and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted-average shares outstanding for the three months ended March 28, 2020 and March 30, 2019 excluded the impact of 0.6 million and 1.0 million shares of non-vested RSUs and PSUs, respectively.

Treasury Shares

During the three months ended March 28, 2020 and March 30, 2019, the Company did not repurchase any shares under its authorized stock repurchase program. As of March 28, 2020, the Company had $129.1 million remaining on the authorized stock repurchase program.

The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. During the three months ended March 28, 2020 and March 30, 2019, the Company acquired 0.1 million shares for $23.7 million and 0.1 million shares for $17.8 million, respectively, from such netting.

Accumulated Other Comprehensive Income (Loss)

Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:


	Foreign Currency Translation Adjustment and Other		Pension and Other Post-Retirement Benefit Plans		Total
	(in thousands)
December 28, 2019	$	(87,578)	$	(90,441)	$	(178,019)
Other comprehensive loss before reclassifications	(44,311)		—		(44,311)
Amounts reclassified from accumulated other comprehensive loss	—		1,374		1,374
Net current period other comprehensive income (loss)	(44,311)		1,374		(42,937)
Income tax expense (benefit)	(2,330)		291		(2,039)
March 28, 2020	$	(129,559)	$	(89,358)	$	(218,917)

Nonredeemable Noncontrolling Interest

The Company has an investment in an entity whose financial results are consolidated in the Company’s unaudited condensed consolidated financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying unaudited condensed consolidated balance sheets. The activity within the nonredeemable noncontrolling interest was immaterial during the three months ended March 28, 2020 and March 30, 2019, respectively.

Redeemable Noncontrolling Interests

The Company has a 92% equity interest in Vital River with an 8% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. These rights are exercisable beginning in 2022 and are accelerated in certain events. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($14.7 million as of March 28, 2020) and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 8% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 8% equity interest is not limited.

As part of the Citoxlab acquisition in 2019, the Company acquired an approximate 90% equity interest in a subsidiary that is fully consolidated under the voting interest model, which included an approximate 10% redeemable noncontrolling interest. In February 2020, the Company purchased the remaining approximate 10% noncontrolling interest for approximately $4 million and assumption of a contingent consideration liability of approximately $2 million payable to the former shareholders. See Note 7. “Fair Value”.

In 2019, the Company acquired an 80% equity interest in a supplier that is fully consolidated, which includes a 20% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 20% equity interest at its appraised value. These rights are exercisable beginning in 2022. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest or a predetermined floor value. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 20% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 20% equity interest is not limited.

The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	28,647	$	18,525
Acquisition of noncontrolling interest	(3,732)		—
Adjustment to Vital River redemption value	—		1,451
Net (loss) income attributable to noncontrolling interests	(332)		85
Foreign currency translation	(544)		458
Ending balance	$	24,039	$	20,519

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 28, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended March 28, 2020 and March 30, 2019 were 8.3% and 16.0%, respectively. For the three months ended March 28, 2020, the decrease was primarily attributable to an increased tax benefit from stock-based compensation deductions compared to the corresponding period in 2019. For the three months ended March 28, 2020, the Company’s unrecognized tax benefits decreased by $0.6 million to $19.1 million, primarily due to tax authority settlements and favorable foreign exchange, offset by an additional quarter of Canadian Scientific Research and Experimental Development Credit reserves. The amount of unrecognized income tax benefits that would impact the effective tax rate decreased by $0.7 million to $16.3 million, for the same reasons listed above. The accrued interest on unrecognized tax benefits was $2.3 million at March 28, 2020. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by up to $3.0 million over the next twelve-month period, primarily due to the outcome of pending tax audits. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2016. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., France and Canada. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

3 Months Ended

Mar. 28, 2020

Retirement Benefits [Abstract]

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Service cost	$	797	$	630
Interest cost	2,355		2,875
Expected return on plan assets	(2,981)		(3,235)
Amortization of prior service cost (credit)	(125)		91
Amortization of net loss	1,586		489
Other adjustments	125		—
Net periodic cost	$	1,757	$	850

Service cost is recorded as an operating expense within the accompanying unaudited condensed consolidated statements of income. All other components of net periodic costs are recorded in Other expense, net in the accompanying unaudited condensed consolidated statements of income. The net periodic cost for the Company’s other post-retirement benefit plan for the three months ended March 28, 2020 and March 30, 2019 was not significant.

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 28, 2020

Share-based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs, and PSUs.

The following table provides stock-based compensation by the financial statement line item in which it is reflected:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Cost of revenue	$	2,035	$	1,949
Selling, general and administrative	8,925		10,950
Stock-based compensation, before income taxes	10,960		12,899
Provision for income taxes	(1,551)		(2,047)
Stock-based compensation, net of income taxes	$	9,409	$	10,852

During the three months ended March 28, 2020, the Company granted an insignificant amount of stock options and RSUs.

FOREIGN CURRENCY CONTRACTS

3 Months Ended

Mar. 28, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FOREIGN CURRENCY CONTRACTS

Cross currency loans

The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility. These contracts are not designated as hedging instruments. Any gains or losses on these forward contracts are recognized immediately in Interest expense in the unaudited condensed consolidated statements of income.

The Company had no open forward contracts related to a U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency at March 28, 2020 or December 28, 2019.

The following table summarizes the effect of the foreign exchange forward contracts entered into to limit the Company’s foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility on the Company’s unaudited condensed consolidated statements of income:


	March 28, 2020						March 30, 2019
Location of gain (loss)	Financial statement caption amount		Amount of gain (loss)		Financial statement caption amount		Amount of gain (loss)
	(in thousands)
Three Months Ended:
Interest expense	$	(15,067)	$	6,067	$	(9,987)	$	8,917

Intercompany loans

The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to certain intercompany loans. These contracts are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other income, net and are largely offset by the remeasurement of the underlying intercompany loans.

The Company entered into foreign currency forward contracts during 2020 and 2019. One contract remained open at December 28, 2019, which had a duration of less than one month and is recorded at fair value in the Company’s accompanying unaudited condensed consolidated balance sheets. The Company did not have any open foreign currency forward contracts related to certain intercompany loans at March 28, 2020. The notional amount and fair value of the open contract is summarized as follows:


December 28, 2019
Notional Amount		Fair Value		Balance Sheet Location
(in thousand)
$	115,038	$	(876)	Other current liabilities

The following table summarizes the effect of the foreign exchange forward contracts in connection with certain intercompany loans on the Company’s unaudited condensed consolidated statements of income:


	March 28, 2020						March 30, 2019
Location of gain (loss)	Financial statement caption amount		Amount of gain (loss)		Financial statement caption amount		Amount of gain (loss)
	(in thousands)
Three Months Ended:
Other (expense) income, net	$	(24,071)	$	(892)	$	6,306	$	—

RESTRUCTURING AND ASSET IMPAIRMENTS

3 Months Ended

Mar. 28, 2020

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND ASSET IMPAIRMENTS

Global Restructuring Initiatives

In recent fiscal years, the Company has undertaken productivity improvement initiatives within all reportable segments at various locations across the U.S., Canada, Europe, China, and Japan. This includes workforce right-sizing and scalability initiatives, resulting in severance and transition costs; and cost related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation charges.

The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income.


	Three Months Ended
	March 28, 2020										March 30, 2019
	Severance and Transition Costs		Asset Impairments and Other Costs		Total		Severance and Transition Costs		Asset Impairments and Other Costs		Total
	(in thousands)
Cost of services provided and products sold (excluding amortization of intangible assets)	$	247	$	229	$	476	$	267	$	1,149	$	1,416
Selling, general and administrative	83		—		83		133		—		133
Total	$	330	$	229	$	559	$	400	$	1,149	$	1,549

The following table presents restructuring costs by reportable segment for these productivity improvement initiatives:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)

RMS	$	220	$	301
DSA	83		13
Manufacturing	256		1,235

Total	$	559	$	1,549

Rollforward of restructuring activities

The following table provides a rollforward for all of the Company’s severance and transition costs, and lease obligation liabilities related to all restructuring activities:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	6,406	$	2,921
Expense (excluding non-cash charges)	517		1,246
Payments / utilization	(4,243)		(2,034)
Foreign currency adjustments	(149)		(20)
Ending balance	$	2,531	$	2,113

As of March 28, 2020 and March 30, 2019, $2.4 million and $1.8 million of severance and other personnel related costs liabilities and lease obligation liabilities, respectively, were included in accrued compensation and accrued liabilities within the Company’s unaudited condensed consolidated balance sheets and $0.1 million and $0.3 million, respectively, were included in other long-term liabilities within the Company’s unaudited condensed consolidated balance sheets.

LEASES

3 Months Ended

Mar. 28, 2020

Leases [Abstract]

LEASES

Operating and Finance Leases

Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows:



	March 28, 2020		December 28, 2019
	(in thousands)
Operating leases
Operating lease right-of-use assets, net	$	155,568	$	140,085

Other current liabilities	$	22,469	$	20,357
Operating lease right-of-use liabilities	133,440		116,252
Total operating lease liabilities	$	155,909	$	136,609

Finance leases
Property, plant and equipment, net	$	30,859	$	32,519

Current portion of long-term debt and finance leases	$	2,929	$	2,997
Long-term debt, net and finance leases	25,879		27,530
Total finance lease liabilities	$	28,808	$	30,527

The components of operating and finance lease costs were as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Operating lease costs	$	8,077	$	7,706
Finance lease costs:
Amortization of right-of-use assets	951		921
Interest on lease liabilities	340		296
Short-term lease costs	589		192
Variable lease costs	1,045		335
Sublease income	(586)		(46)
Total lease costs	$	10,416	$	9,404

Other information related to leases was as follows:

Supplemental cash flow information


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,974	$	6,533
Operating cash flows from finance leases	340		352
Finance cash flows from finance leases	1,572		838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	25,407	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	593		—

Lease term and discount rate


						As of
						March 28, 2020
Weighted-average remaining lease term (in years)
Operating lease						8.40
Finance lease						12.71
Weighted-average discount rate
Operating lease						4.24
Finance lease						4.54

At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate.

As of March 28, 2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:


	Operating Leases		Finance Leases
	(in thousands)
2020 (excluding the three months ended March 28, 2020)	$	21,347	$	3,063
2021	27,308		3,804
2022	23,483		3,754
2023	19,810		2,898
2024	19,168		2,146
Thereafter	76,170		22,531
Total minimum future lease payments	187,286		38,196
Less: Imputed interest	31,377		9,388
Total lease liabilities	$	155,909	$	28,808

Total minimum future lease payments (predominantly operating leases) of approximately $48 million for leases that have not commenced as of March 28, 2020, as the Company does not yet control the underlying assets, are not included in the unaudited condensed consolidated financial statements. These leases are expected to commence between fiscal years 2020 and 2024 with lease terms of approximately 2 to 15 years.

LEASES

Operating and Finance Leases

Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows:



	March 28, 2020		December 28, 2019
	(in thousands)
Operating leases
Operating lease right-of-use assets, net	$	155,568	$	140,085

Other current liabilities	$	22,469	$	20,357
Operating lease right-of-use liabilities	133,440		116,252
Total operating lease liabilities	$	155,909	$	136,609

Finance leases
Property, plant and equipment, net	$	30,859	$	32,519

Current portion of long-term debt and finance leases	$	2,929	$	2,997
Long-term debt, net and finance leases	25,879		27,530
Total finance lease liabilities	$	28,808	$	30,527

The components of operating and finance lease costs were as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Operating lease costs	$	8,077	$	7,706
Finance lease costs:
Amortization of right-of-use assets	951		921
Interest on lease liabilities	340		296
Short-term lease costs	589		192
Variable lease costs	1,045		335
Sublease income	(586)		(46)
Total lease costs	$	10,416	$	9,404

Other information related to leases was as follows:

Supplemental cash flow information


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,974	$	6,533
Operating cash flows from finance leases	340		352
Finance cash flows from finance leases	1,572		838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	25,407	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	593		—

Lease term and discount rate


						As of
						March 28, 2020
Weighted-average remaining lease term (in years)
Operating lease						8.40
Finance lease						12.71
Weighted-average discount rate
Operating lease						4.24
Finance lease						4.54

As of March 28, 2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:


	Operating Leases		Finance Leases
	(in thousands)
2020 (excluding the three months ended March 28, 2020)	$	21,347	$	3,063
2021	27,308		3,804
2022	23,483		3,754
2023	19,810		2,898
2024	19,168		2,146
Thereafter	76,170		22,531
Total minimum future lease payments	187,286		38,196
Less: Imputed interest	31,377		9,388
Total lease liabilities	$	155,909	$	28,808

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 28, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition.

BASIS OF PRESENTATION (Policies)	3 Months Ended
BASIS OF PRESENTATION (Policies)	Mar. 28, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The COVID-19 pandemic is dynamic and expanding, and its ultimate scope, duration and effects are uncertain. This pandemic has and continues to result in, and any future epidemic or pandemic crises may potentially result in, direct and indirect adverse effects on the Company’s industry and customers, which in turn has (with respect to COVID-19) and may (with respect to future epidemics or crises) impact the Company’s business, results of operations and financial condition. Further, the COVID-19 pandemic may also affect the Company’s operating and financial results in a manner that is not presently known to the Company or that the Company currently does not expect to present significant risks to its operations or financial results. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.
Consolidation	The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Fiscal Period	The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31.
Segment Reporting	The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research Products businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services). Research Products supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Testing Services (Biologics), which performs specialized testing of biologics; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens.
Newly Adopted and Newly Issued Accounting Pronouncements	In August 2018, the Financial Accounting Standards Board (FASB) issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computer Arrangement that is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes the disclosure requirement for the amount and reasons for transfers between Level 1 and Level 2 fair value measurements as well as the process for Level 3 fair value measurements. In addition, the ASU adds the disclosure requirements for changes in unrealized gains and losses included in Other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period as well as the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20).” ASU 2018-14 removes the requirements to disclose the amounts in Accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and the related party disclosures about the amount of future annual benefits covered by insurance contracts. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. This standard became effective for the Company in the three months ended March 28, 2020 and did not have an impact on the unaudited condensed consolidated financial statements and related disclosures. The Company performs its annual impairment test during the fourth quarter of a fiscal year and does not expect any significant impact on the consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses”. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as trade and notes receivables, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This standard became effective for the Company in the three months ended March 28, 2020 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU offers temporary optional expedients and exceptions for applying U.S. GAAP to modifications to agreements such as loans, debt securities, derivatives, and borrowings which reference LIBOR or another reference rate that is expected to be discontinued by December 31, 2021. The expedients and exceptions provided by the standard do not apply to modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for hedging relationships existing as of December 31, 2022 that an entity has elected certain optional expedients for and are retained through the end of the hedging relationship. The ASU is effective until December 31, 2022 when the replacement for LIBOR is expected to be completed. The interest rate on the Company’s senior credit facility, which matures in fiscal year 2023, is linked to LIBOR. The Company is in the process of evaluating options for transitioning away from the senior credit facility’s use of LIBOR and expects to be completed by the time LIBOR is phased out. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures and has yet to elect an adoption date. In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied either retrospectively or prospectively based upon the applicable amendments. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.

BUSINESS ACQUISITIONS (Tables)

3 Months Ended

Mar. 28, 2020

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

The purchase allocation of $490.4 million, net of $36.7 million of cash acquired was as follows:


	April 29, 2019
	(in thousands)
Trade receivables	$	35,405
Inventories	5,282
Other current assets (excluding cash)	13,917
Property, plant and equipment	88,605
Goodwill	280,161
Definite-lived intangible assets	162,400
Other long-term assets	20,063
Deferred revenue	(15,278)
Current liabilities	(46,081)
Deferred tax liabilities	(27,458)
Other long-term liabilities	(22,624)
Redeemable noncontrolling interest	(4,035)
Total purchase price allocation	$	490,357

The purchase allocation of $23.1 million, net of $0.3 million of cash acquired was as follows:


	August 28, 2019
	(in thousands)
Trade receivables	$	189
Inventories	7,644
Property, plant and equipment	1,462
Goodwill	12,669
Other long-term assets	11,849
Current liabilities	(441)
Deferred tax liabilities	(1,331)
Other long-term liabilities	(238)
Redeemable noncontrolling interest	(8,740)
Total purchase price allocation	$	23,063

Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination

The breakout of definite-lived intangible assets acquired was as follows:


	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	170,390	19
Trade name	7,330		10
Other intangible assets	5,820		3
Total definite-lived intangible assets	$	183,540	18

The breakout of definite-lived intangible assets acquired was as follows:


	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	134,600	13
Developed technology	19,900		3
Backlog	7,900		1
Total definite-lived intangible assets	$	162,400	12

Schedule of Business Acquisition, Pro Forma Information


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
	(unaudited)
Revenue	$	707,077	$	613,456
Net income attributable to common shareholders	55,705		52,186

Three Months Ended

March 30, 2019

(in thousands)

(unaudited)

Revenue

650,875

Net income attributable to common shareholders

61,028

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)

3 Months Ended

Mar. 28, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Major Products/Service Lines:
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	60,041	$	54,813
Services and products transferred at a point in time	85,955		82,359
DSA
Services and products transferred over time	438,564		354,078
Services and products transferred at a point in time	119		119
Manufacturing
Services and products transferred over time	37,314		31,896
Services and products transferred at a point in time	85,066		81,304
Total revenue	$	707,059	$	604,569

Revenue for each significant product or service offering is as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569

Revenue by geographic area is as follows:


	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 28, 2020	$	406,712	$	190,262	$	76,633	$	31,829	$	1,623	$	707,059
March 30, 2019	350,176		166,365		53,979		33,179		870		604,569

Schedule of Estimated Revenue Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 28, 2020:


	Revenue Expected to be Recognized in Future Periods
	Less than 1 Year		1 to 3 Years		4 to 5 Years		Beyond 5 Years		Total
	(in thousands)
DSA	$	195,192	$	92,180	$	4,861	$	639	$	292,872
Manufacturing	10,241		8,825		32		21		19,119
Total	$	205,433	$	101,005	$	4,893	$	660	$	311,991

Schedule of Client Receivables, Contract Assets and Contract Liabilities

The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:


	March 28, 2020		December 28, 2019
	(in thousands)
Balances from contracts with customers:
Client receivables	$	415,359	$	395,740
Contract assets (unbilled revenue)	131,660		121,957
Contract liabilities (current and long-term deferred revenue)	194,907		192,788
Contract liabilities (customer contract deposits)	37,319		33,080

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 28, 2020

Segment Reporting [Abstract]

Schedule of Revenue and Other Financial Information by Business Segment

The following table presents revenue and other financial information by reportable segment:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
RMS
Revenue	$	145,996	$	137,172
Operating income	27,373		37,832
Depreciation and amortization	8,752		4,322
Capital expenditures	5,412		4,112
DSA
Revenue	$	438,683	$	354,197
Operating income	72,283		46,705
Depreciation and amortization	41,330		33,784
Capital expenditures	14,729		8,848
Manufacturing
Revenue	$	122,380	$	113,200
Operating income	41,112		31,499
Depreciation and amortization	6,366		5,805
Capital expenditures	5,161		3,606

Reconciliation of Segment Operating Income to Consolidated Operating Income

Reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows:


	Operating Income						Depreciation and Amortization						Capital Expenditures
	March 28, 2020		March 30, 2019		March 28, 2020		March 30, 2019		March 28, 2020		March 30, 2019
	(in thousands)
Three Months Ended:
Total reportable segments	$	140,768	$	116,036	$	56,448	$	43,911	$	25,302	$	16,566
Unallocated corporate	(46,487)		(46,244)		812		1,447		419		165
Total consolidated	$	94,281	$	69,792	$	57,260	$	45,358	$	25,721	$	16,731

Revenue Disaggregated by Products and Services and Geographic Area

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Major Products/Service Lines:
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	60,041	$	54,813
Services and products transferred at a point in time	85,955		82,359
DSA
Services and products transferred over time	438,564		354,078
Services and products transferred at a point in time	119		119
Manufacturing
Services and products transferred over time	37,314		31,896
Services and products transferred at a point in time	85,066		81,304
Total revenue	$	707,059	$	604,569

Revenue for each significant product or service offering is as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
RMS	$	145,996	$	137,172
DSA	438,683		354,197
Manufacturing	122,380		113,200
Total revenue	$	707,059	$	604,569

Revenue by geographic area is as follows:


	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 28, 2020	$	406,712	$	190,262	$	76,633	$	31,829	$	1,623	$	707,059
March 30, 2019	350,176		166,365		53,979		33,179		870		604,569

Summary of Unallocated Corporate Overhead

A summary of unallocated corporate expense consists of the following:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Stock-based compensation	$	6,704	$	8,274
Compensation, benefits, and other employee-related expenses	21,980		22,038
External consulting and other service expenses	2,469		3,810
Information technology	3,716		2,723
Depreciation	812		1,447
Acquisition and integration	6,983		5,472
Other general unallocated corporate	3,823		2,480
Total unallocated corporate expense	$	46,487	$	46,244

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)

3 Months Ended

Mar. 28, 2020

Supplemental Balance Sheet Information [Abstract]

Composition of Net Trade Receivables

The composition of trade receivables, net is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Client receivables	$	415,359	$	395,740
Unbilled revenue	131,660		121,957
Total	547,019		517,697
Less: Allowance for doubtful accounts	(4,629)		(3,664)
Trade receivables, net	$	542,390	$	514,033

Composition of Inventories

The composition of inventories is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Raw materials and supplies	$	24,708	$	24,613
Work in process	30,418		35,852
Finished products	107,812		100,195
Inventories	$	162,938	$	160,660

Composition of Other Current Assets

The composition of other current assets is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Prepaid income tax	$	60,016	$	54,358
Short-term investments	934		941
Restricted cash	444		431
Other	300		300
Other current assets	$	61,694	$	56,030

Composition of Other Assets

The composition of other assets is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Venture capital investments	$	98,405	$	108,983
Other investments	18,659		13,996
Life insurance policies	31,617		38,207
Other long-term income tax assets	20,534		20,570
Restricted cash	1,576		1,601
Other	26,288		29,258
Other assets	$	197,079	$	212,615

Composition of Other Current Liabilities

The composition of other current liabilities is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
Current portion of operating lease right-of-use liabilities	$	22,469	$	20,357
Accrued income taxes	25,706		26,066
Customer contract deposits	37,319		33,080
Other	23,426		11,095
Other current liabilities	$	108,920	$	90,598

Composition of Other Long-Term Liabilities

he composition of other long-term liabilities is as follows:


	March 28, 2020		December 28, 2019
	(in thousands)
U.S. Transition Tax	$	50,057	$	52,066
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan	78,272		80,833
Long-term deferred revenue	16,078		20,983
Other	29,517		29,051
Other long-term liabilities	$	173,924	$	182,933

FAIR VALUE (Tables)

3 Months Ended

Mar. 28, 2020

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and liabilities measured at fair value on a recurring basis are summarized below:


	March 28, 2020
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	186,599	$	—	$	186,599
Other assets:
Life insurance policies	—		23,834		—		23,834
Total assets measured at fair value	$	—	$	210,433	$	—	$	210,433

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	2,563	$	2,563
Total liabilities measured at fair value	$	—	$	—	$	2,563	$	2,563


	December 28, 2019
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	55,278	$	—	$	55,278
Other assets:
Life insurance policies	—		30,454		—		30,454
Total assets measured at fair value	$	—	$	85,732	$	—	$	85,732

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	712	$	712
Foreign currency forward contract	—		876		—		876
Total liabilities measured at fair value	$	—	$	876	$	712	$	1,588

The book value and fair value of the Company’s 2026 and 2028 Senior Notes is summarized below:


	March 28, 2020						December 28, 2019
	Book Value		Fair Value		Book Value		Fair Value
2026 Senior Notes	$	500,000	$	508,050	$	500,000	$	537,500
2028 Senior Notes	500,000		475,000		500,000		510,000

Rollforward of Contingent Consideration Related to Previous Acquisitions

The following table provides a rollforward of the contingent consideration related to previous business acquisitions. See Note 2, “Business Combinations.”


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	712	$	3,033
Additions	2,131		2,000
Payments	(218)		(2,610)
Foreign currency	(62)		74
Ending balance	$	2,563	$	2,497

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 28, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Rollforward of Goodwill

The following table provides a rollforward of the Company’s goodwill:


			Adjustments to Goodwill
	December 28, 2019		Acquisitions		Foreign Exchange		March 28, 2020
	(in thousands)
RMS	$	56,586	$	209,104	$	(219)	$	265,471
DSA	1,345,223		(550)		(13,865)		1,330,808
Manufacturing	138,756		—		(3,198)		135,558
Goodwill	$	1,540,565	$	208,554	$	(17,282)	$	1,731,837

Schedule of Intangible Assets

The following table displays intangible assets, net by major class:


	March 28, 2020										December 28, 2019
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
	(in thousands)
Backlog	$	28,558	$	(27,133)	$	1,425	$	28,865	$	(26,895)	$	1,970
Technology	123,647		(62,307)		61,340		122,106		(57,737)		64,369
Trademarks and trade names	15,504		(4,983)		10,521		8,430		(4,901)		3,529
Other	19,874		(12,813)		7,061		18,279		(12,307)		5,972
Other intangible assets	187,583		(107,236)		80,347		177,680		(101,840)		75,840
Client relationships	1,085,540		(333,024)		752,516		934,668		(321,095)		613,573
Intangible assets	$	1,273,123	$	(440,260)	$	832,863	$	1,112,348	$	(422,935)	$	689,413

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 28, 2020

Debt Disclosure [Abstract]

Schedule of Long-term Debt and Finance Lease Obligations

Long-term debt, net and finance leases consists of the following:


	March 28, 2020		December 28, 2019
	(in thousands)
Term loans	$	184,375	$	193,750
Revolving facility	1,168,096		676,134
2026 Senior Notes	500,000		500,000
2028 Senior Notes	500,000		500,000
Other debt	10,227		5,781
Finance leases (Note 16)	28,808		30,527
Total debt and finance leases	2,391,506		1,906,192
Less:
Current portion of long-term debt	44,738		35,548
Current portion of finance leases (Note 16)	2,929		2,997
Current portion of long-term debt and finance leases	47,667		38,545
Long-term debt and finance leases	2,343,839		1,867,647
Debt discount and debt issuance costs	(17,069)		(17,981)
Long-term debt, net and finance leases	$	2,326,770	$	1,849,666

EQUITY AND NONCONTROLLING INTERESTS (Tables)

3 Months Ended

Mar. 28, 2020

Equity [Abstract]

Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Numerator:
Net income	$	50,837	$	55,688
Less: Net income attributable to noncontrolling interests	68		555
Net income attributable to common shareholders	$	50,769	$	55,133

Denominator:
Weighted-average shares outstanding - Basic	49,189		48,458
Effect of dilutive securities:
Stock options, restricted stock units and performance share units	777		1,004
Weighted-average shares outstanding - Diluted	49,966		49,462

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:


	Foreign Currency Translation Adjustment and Other		Pension and Other Post-Retirement Benefit Plans		Total
	(in thousands)
December 28, 2019	$	(87,578)	$	(90,441)	$	(178,019)
Other comprehensive loss before reclassifications	(44,311)		—		(44,311)
Amounts reclassified from accumulated other comprehensive loss	—		1,374		1,374
Net current period other comprehensive income (loss)	(44,311)		1,374		(42,937)
Income tax expense (benefit)	(2,330)		291		(2,039)
March 28, 2020	$	(129,559)	$	(89,358)	$	(218,917)

Rollforward Redeemable Noncontrolling Interest

The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	28,647	$	18,525
Acquisition of noncontrolling interest	(3,732)		—
Adjustment to Vital River redemption value	—		1,451
Net (loss) income attributable to noncontrolling interests	(332)		85
Foreign currency translation	(544)		458
Ending balance	$	24,039	$	20,519

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Tables)

3 Months Ended

Mar. 28, 2020

Retirement Benefits [Abstract]

Schedule of Net Periodic Cost

The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Service cost	$	797	$	630
Interest cost	2,355		2,875
Expected return on plan assets	(2,981)		(3,235)
Amortization of prior service cost (credit)	(125)		91
Amortization of net loss	1,586		489
Other adjustments	125		—
Net periodic cost	$	1,757	$	850

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 28, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Expense

The following table provides stock-based compensation by the financial statement line item in which it is reflected:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Cost of revenue	$	2,035	$	1,949
Selling, general and administrative	8,925		10,950
Stock-based compensation, before income taxes	10,960		12,899
Provision for income taxes	(1,551)		(2,047)
Stock-based compensation, net of income taxes	$	9,409	$	10,852

FOREIGN CURRENCY CONTRACTS (Tables)

3 Months Ended

12 Months Ended

Mar. 28, 2020

Dec. 28, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments on Statements of Income


	March 28, 2020						March 30, 2019
Location of gain (loss)	Financial statement caption amount		Amount of gain (loss)		Financial statement caption amount		Amount of gain (loss)
	(in thousands)
Three Months Ended:
Interest expense	$	(15,067)	$	6,067	$	(9,987)	$	8,917


	March 28, 2020						March 30, 2019
Location of gain (loss)	Financial statement caption amount		Amount of gain (loss)		Financial statement caption amount		Amount of gain (loss)
	(in thousands)
Three Months Ended:
Other (expense) income, net	$	(24,071)	$	(892)	$	6,306	$	—

Schedule of Notional and Fair Value of Foreign Currency Contracts


December 28, 2019
Notional Amount		Fair Value		Balance Sheet Location
(in thousand)
$	115,038	$	(876)	Other current liabilities

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)

3 Months Ended

Mar. 28, 2020

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Costs

The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income.


	Three Months Ended
	March 28, 2020										March 30, 2019
	Severance and Transition Costs		Asset Impairments and Other Costs		Total		Severance and Transition Costs		Asset Impairments and Other Costs		Total
	(in thousands)
Cost of services provided and products sold (excluding amortization of intangible assets)	$	247	$	229	$	476	$	267	$	1,149	$	1,416
Selling, general and administrative	83		—		83		133		—		133
Total	$	330	$	229	$	559	$	400	$	1,149	$	1,549

The following table presents restructuring costs by reportable segment for these productivity improvement initiatives:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)

RMS	$	220	$	301
DSA	83		13
Manufacturing	256		1,235

Total	$	559	$	1,549

Rollforward of Company's Severance and Transition Costs and Lease Obligation Liabilities

The following table provides a rollforward for all of the Company’s severance and transition costs, and lease obligation liabilities related to all restructuring activities:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Beginning balance	$	6,406	$	2,921
Expense (excluding non-cash charges)	517		1,246
Payments / utilization	(4,243)		(2,034)
Foreign currency adjustments	(149)		(20)
Ending balance	$	2,531	$	2,113

LEASES (Tables)

3 Months Ended

Mar. 28, 2020

Leases [Abstract]

Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements

Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows:



	March 28, 2020		December 28, 2019
	(in thousands)
Operating leases
Operating lease right-of-use assets, net	$	155,568	$	140,085

Other current liabilities	$	22,469	$	20,357
Operating lease right-of-use liabilities	133,440		116,252
Total operating lease liabilities	$	155,909	$	136,609

Finance leases
Property, plant and equipment, net	$	30,859	$	32,519

Current portion of long-term debt and finance leases	$	2,929	$	2,997
Long-term debt, net and finance leases	25,879		27,530
Total finance lease liabilities	$	28,808	$	30,527

Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information

The components of operating and finance lease costs were as follows:


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Operating lease costs	$	8,077	$	7,706
Finance lease costs:
Amortization of right-of-use assets	951		921
Interest on lease liabilities	340		296
Short-term lease costs	589		192
Variable lease costs	1,045		335
Sublease income	(586)		(46)
Total lease costs	$	10,416	$	9,404

Supplemental cash flow information


	Three Months Ended
	March 28, 2020		March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,974	$	6,533
Operating cash flows from finance leases	340		352
Finance cash flows from finance leases	1,572		838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	25,407	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	593		—

Lease term and discount rate


						As of
						March 28, 2020
Weighted-average remaining lease term (in years)
Operating lease						8.40
Finance lease						12.71
Weighted-average discount rate
Operating lease						4.24
Finance lease						4.54

Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases

As of March 28, 2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:


	Operating Leases		Finance Leases
	(in thousands)
2020 (excluding the three months ended March 28, 2020)	$	21,347	$	3,063
2021	27,308		3,804
2022	23,483		3,754
2023	19,810		2,898
2024	19,168		2,146
Thereafter	76,170		22,531
Total minimum future lease payments	187,286		38,196
Less: Imputed interest	31,377		9,388
Total lease liabilities	$	155,909	$	28,808

Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases

As of March 28, 2020, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows:


	Operating Leases		Finance Leases
	(in thousands)
2020 (excluding the three months ended March 28, 2020)	$	21,347	$	3,063
2021	27,308		3,804
2022	23,483		3,754
2023	19,810		2,898
2024	19,168		2,146
Thereafter	76,170		22,531
Total minimum future lease payments	187,286		38,196
Less: Imputed interest	31,377		9,388
Total lease liabilities	$	155,909	$	28,808

BASIS OF PRESENTATION (Details)	3 Months Ended
BASIS OF PRESENTATION (Details)	Mar. 28, 2020 segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	3

BUSINESS ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands				3 Months Ended
	Jan. 03, 2020	Aug. 28, 2019	Apr. 29, 2019	Mar. 28, 2020	Mar. 30, 2019	Dec. 28, 2019
HemaCare Corporation
Business Acquisition [Line Items]
Purchase price	$ 379,800
Purchase price allocation	376,721
Cash acquired	$ 3,100
Integration related costs and transaction costs				$ 5,700
Actual revenue from acquiree				12,300
Operating income (loss) from acquiree				(2,200)
Citoxlab
Business Acquisition [Line Items]
Purchase price			$ 527,100
Purchase price allocation			490,357
Cash acquired			36,700
Integration related costs and transaction costs				1,400	$ 5,200
Actual revenue from acquiree				45,300	2,500
Goodwill, amount expected to be deductible for tax purposes			$ 7,200
Other Acquisitions
Business Acquisition [Line Items]
Purchase price		$ 23,400
Purchase price allocation		23,063
Cash acquired		300
Integration related costs and transaction costs				0
Prepayments for future purchases and other post-closing adjustments		$ 4,000
Depreciation and Amortization Expense \| HemaCare Corporation
Business Acquisition [Line Items]
Adjustments related to prior period				$ 200	3,200
Depreciation and Amortization Expense \| Citoxlab
Business Acquisition [Line Items]
Adjustments related to prior period					2,600
Interest Expense \| HemaCare Corporation
Business Acquisition [Line Items]
Adjustments related to prior period					2,800
Interest Expense \| Citoxlab
Business Acquisition [Line Items]
Adjustments related to prior period					$ 1,200
Supplier
Business Acquisition [Line Items]
Equity interest						80.00%
Noncontrolling interest ownership percentage						20.00%
Supplier \| Other Acquisitions
Business Acquisition [Line Items]
Equity interest		80.00%
Noncontrolling interest ownership percentage		20.00%

BUSINESS ACQUISITIONS - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Jan. 03, 2020	Dec. 28, 2019	Aug. 28, 2019	Apr. 29, 2019
Business Acquisition [Line Items]
Goodwill	$ 1,731,837		$ 1,540,565
HemaCare Corporation
Business Acquisition [Line Items]
Trade receivables		$ 6,451
Inventories		8,468
Other current assets (excluding cash)		3,527
Property, plant and equipment		10,033
Goodwill		209,104
Definite-lived intangible assets		183,540
Other long-term assets		5,920
Current liabilities		(5,188)
Deferred tax liabilities		(37,470)
Other long-term liabilities		(7,664)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total		$ 376,721
Citoxlab
Business Acquisition [Line Items]
Trade receivables					$ 35,405
Inventories					5,282
Other current assets (excluding cash)					13,917
Property, plant and equipment					88,605
Goodwill					280,161
Definite-lived intangible assets					162,400
Other long-term assets					20,063
Deferred revenue					(15,278)
Current liabilities					(46,081)
Deferred tax liabilities					(27,458)
Other long-term liabilities					(22,624)
Redeemable noncontrolling interest					(4,035)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total					$ 490,357
Other Acquisitions
Business Acquisition [Line Items]
Trade receivables				$ 189
Inventories				7,644
Property, plant and equipment				1,462
Goodwill				12,669
Other long-term assets				11,849
Current liabilities				(441)
Deferred tax liabilities				(1,331)
Other long-term liabilities				(238)
Redeemable noncontrolling interest				(8,740)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total				$ 23,063

BUSINESS ACQUISITIONS - Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jan. 03, 2020	Apr. 29, 2019
HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 183,540
Weighted-average amortization life	18 years
Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 162,400
Weighted-average amortization life		12 years
Customer Relationships \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 170,390
Weighted-average amortization life	19 years
Customer Relationships \| Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 134,600
Weighted-average amortization life		13 years
Trade Name \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 7,330
Weighted-average amortization life	10 years
Other Intangible Assets \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 5,820
Weighted-average amortization life	3 years
Developed Technology \| Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 19,900
Weighted-average amortization life		3 years
Backlog \| Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 7,900
Weighted-average amortization life		1 year

BUSINESS ACQUISITIONS - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
HemaCare Corporation
Business Acquisition [Line Items]
Revenue	$ 707,077	$ 613,456
Net income attributable to common shareholders	$ 55,705	52,186
Citoxlab
Business Acquisition [Line Items]
Revenue		650,875
Net income attributable to common shareholders		$ 61,028

REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 707,059	$ 604,569
RMS
Disaggregation of Revenue [Line Items]
Total revenue	145,996	137,172
RMS \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	60,041	54,813
RMS \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	85,955	82,359
DSA
Disaggregation of Revenue [Line Items]
Total revenue	438,683	354,197
DSA \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	438,564	354,078
DSA \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	119	119
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	122,380	113,200
Manufacturing \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	37,314	31,896
Manufacturing \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 85,066	$ 81,304

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Dec. 28, 2019
Revenue from Contract with Customer [Abstract]
Payment terms	30 days
Unpaid advanced client billings	$ 19,000	$ 27,000
Contract liabilities (customer contract deposits)	$ 37,319	$ 33,080
Percentage of unbilled revenue billed during period	60.00%
Percentage of contract liabilities recognized as revenue during period	60.00%

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Revenue from Contract with Customer [Abstract]
Client receivables	$ 415,359	$ 395,740
Contract assets (unbilled revenue)	131,660	121,957
Contract liabilities (current and long-term deferred revenue)	194,907	192,788
Contract liabilities (customer contract deposits)	$ 37,319	$ 33,080

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Mar. 28, 2020 segments
Segment Reporting [Abstract]
Number of reportable segments	3

SEGMENT INFORMATION - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 707,059	$ 604,569
Operating income	94,281	69,792
Depreciation and amortization	57,260	45,358
Capital expenditures	25,721	16,731
RMS
Segment Reporting Information [Line Items]
Revenue	145,996	137,172
Operating income	27,373	37,832
Depreciation and amortization	8,752	4,322
Capital expenditures	5,412	4,112
DSA
Segment Reporting Information [Line Items]
Revenue	438,683	354,197
Operating income	72,283	46,705
Depreciation and amortization	41,330	33,784
Capital expenditures	14,729	8,848
Manufacturing
Segment Reporting Information [Line Items]
Revenue	122,380	113,200
Operating income	41,112	31,499
Depreciation and amortization	6,366	5,805
Capital expenditures	$ 5,161	$ 3,606

SEGMENT INFORMATION - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Operating income	$ 94,281	$ 69,792
Depreciation and amortization	57,260	45,358
Capital expenditures	25,721	16,731
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	140,768	116,036
Depreciation and amortization	56,448	43,911
Capital expenditures	25,302	16,566
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(46,487)	(46,244)
Depreciation and amortization	812	1,447
Capital expenditures	$ 419	$ 165

SEGMENT INFORMATION - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Total revenue	$ 707,059	$ 604,569
RMS
Segment Reporting Information [Line Items]
Total revenue	145,996	137,172
DSA
Segment Reporting Information [Line Items]
Total revenue	438,683	354,197
Manufacturing
Segment Reporting Information [Line Items]
Total revenue	$ 122,380	$ 113,200

SEGMENT INFORMATION - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Stock-based compensation	$ 10,960	$ 12,899
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	6,704	8,274
Compensation, benefits, and other employee-related expenses	21,980	22,038
External consulting and other service expenses	2,469	3,810
Information technology	3,716	2,723
Depreciation	812	1,447
Acquisition and integration	6,983	5,472
Other general unallocated corporate	3,823	2,480
Total unallocated corporate expense	$ 46,487	$ 46,244

SEGMENT INFORMATION - Disaggregation of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 707,059	$ 604,569
U.S.
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	406,712	350,176
Europe
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	190,262	166,365
Canada
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	76,633	53,979
Asia Pacific
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	31,829	33,179
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 1,623	$ 870

SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019	Mar. 30, 2019
Composition of trade receivables
Client receivables	$ 415,359	$ 395,740
Unbilled revenue	131,660	121,957
Total	547,019	517,697
Less: Allowance for doubtful accounts	(4,629)	(3,664)
Trade receivables, net	542,390	514,033
Composition of inventories
Raw materials and supplies	24,708	24,613
Work in process	30,418	35,852
Finished products	107,812	100,195
Inventories	162,938	160,660
Composition of other current assets
Prepaid income tax	60,016	54,358
Short-term investments	934	941
Restricted cash	444	431	$ 491
Other	300	300
Other current assets	61,694	56,030
Composition of other assets
Venture capital investments	98,405	108,983
Other investments	18,659	13,996
Life insurance policies	31,617	38,207
Other long-term income tax assets	20,534	20,570
Restricted cash	1,576	1,601	$ 1,499
Other	26,288	29,258
Other assets	197,079	212,615
Composition of other current liabilities
Current portion of operating lease right-of-use liabilities	22,469	20,357
Accrued income taxes	25,706	26,066
Customer contract deposits	37,319	33,080
Other	23,426	11,095
Other current liabilities	108,920	90,598
Composition of other long-term liabilities
U.S. Transition Tax	50,057	52,066
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan	78,272	80,833
Long-term deferred revenue	16,078	20,983
Other	29,517	29,051
Other long-term liabilities	$ 173,924	$ 182,933

VENTURE CAPITAL AND OTHER INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Dec. 28, 2019
Equity Method Investments and Joint Ventures [Abstract]
Venture capital investments	$ 98,405		$ 108,983
Committed contribution	128,400
Amount funded for venture capital investments	82,900
Dividends received	900	$ 800
Gains (losses) recognized from venture capital investments	(12,200)	$ 10,600
Other equity investments	$ 18,659		$ 13,996

FAIR VALUE - Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 186,599	$ 55,278
Other assets:
Life insurance policies	23,834	30,454
Total assets measured at fair value	210,433	85,732
Other current liabilities measured at fair value:
Contingent consideration	2,563	712
Foreign currency forward contract		876
Total liabilities measured at fair value	2,563	1,588
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	0	0
Foreign currency forward contract		0
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	186,599	55,278
Other assets:
Life insurance policies	23,834	30,454
Total assets measured at fair value	210,433	85,732
Other current liabilities measured at fair value:
Contingent consideration	0	0
Foreign currency forward contract		876
Total liabilities measured at fair value	0	876
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	2,563	712
Foreign currency forward contract		0
Total liabilities measured at fair value	$ 2,563	$ 712

FAIR VALUE - Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 712	$ 3,033
Additions	2,131	2,000
Payments	(218)	(2,610)
Foreign currency	(62)	74
Ending balance	$ 2,563	$ 2,497

FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019	Dec. 29, 2018
2026 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	5.50%		5.50%
2026 Senior Notes \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
2026 Senior Notes \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 508,050	$ 537,500
2028 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.25%	4.25%
2028 Senior Notes \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
2028 Senior Notes \| Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 475,000	$ 510,000

GOODWILL AND INTANGIBLE ASSETS - Rollforward of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 28, 2020 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 1,540,565
Acquisitions	208,554
Foreign exchange	(17,282)
Ending balance	1,731,837
RMS
Goodwill [Roll Forward]
Beginning balance	56,586
Acquisitions	209,104
Foreign exchange	(219)
Ending balance	265,471
DSA
Goodwill [Roll Forward]
Beginning balance	1,345,223
Acquisitions	(550)
Foreign exchange	(13,865)
Ending balance	1,330,808
Manufacturing
Goodwill [Roll Forward]
Beginning balance	138,756
Acquisitions	0
Foreign exchange	(3,198)
Ending balance	$ 135,558

GOODWILL AND INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Other intangible assets
Gross	$ 1,273,123	$ 1,112,348
Accumulated Amortization	(440,260)	(422,935)
Net	832,863	689,413
Backlog
Other intangible assets
Gross	28,558	28,865
Accumulated Amortization	(27,133)	(26,895)
Net	1,425	1,970
Technology
Other intangible assets
Gross	123,647	122,106
Accumulated Amortization	(62,307)	(57,737)
Net	61,340	64,369
Trademarks and trade names
Other intangible assets
Gross	15,504	8,430
Accumulated Amortization	(4,983)	(4,901)
Net	10,521	3,529
Other
Other intangible assets
Gross	19,874	18,279
Accumulated Amortization	(12,813)	(12,307)
Net	7,061	5,972
Other intangible assets
Other intangible assets
Gross	187,583	177,680
Accumulated Amortization	(107,236)	(101,840)
Net	80,347	75,840
Customer Relationships
Other intangible assets
Gross	1,085,540	934,668
Accumulated Amortization	(333,024)	(321,095)
Net	$ 752,516	$ 613,573

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Finance leases	$ 28,808	$ 30,527
Total debt and finance leases	2,391,506	1,906,192
Current portion of long-term debt	44,738	35,548
Current portion of finance leases	2,929	2,997
Current portion of long-term debt and finance leases	47,667	38,545
Long-term debt and finance leases	2,343,839	1,867,647
Debt discount and debt issuance costs	(17,069)	(17,981)
Long-term debt, net and finance leases	2,326,770	1,849,666
Term Loans
Debt Instrument [Line Items]
Long-term debt, gross	184,375	193,750
Revolving Facility
Debt Instrument [Line Items]
Long-term debt, gross	1,168,096	676,134
Senior Notes \| 2026 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	500,000	500,000
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	500,000	500,000
Other Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 10,227	$ 5,781

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Narrative (Details)			3 Months Ended
	Oct. 23, 2019 USD ($)	Mar. 26, 2018	Mar. 28, 2020 USD ($) payment	Mar. 30, 2019 USD ($)	Dec. 28, 2019 USD ($)	Nov. 04, 2019	Dec. 29, 2018 USD ($)
Debt Instrument [Line Items]
Weighted average interest rate			3.03%		3.46%
Number of consecutive fiscal quarters			1 year
$2.8 Billion Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Credit facility			$ 2,800,000,000
Maximum borrowing capacity, term loan and line of credit facility, potential increase available			1,000,000,000.0
$750 Million Term Loan \| Credit Facility
Debt Instrument [Line Items]
Credit facility			$ 750,000,000
Number of quarterly installment payments \| payment			19
Prepayments of long-term debt	$ 500,000,000.0
$2.05 Billion Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Minimum EBITDA less capital expenditures to consolidated cash interest expense ratio		3.50
$2.05 Billion Credit Facility \| Credit Facility \| Federal Funds Rate
Debt Instrument [Line Items]
Variable interest rate		0.50%
$2.05 Billion Credit Facility \| Credit Facility \| LIBOR
Debt Instrument [Line Items]
Variable interest rate		1.00%
$2.05 Billion Credit Facility \| Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility			$ 2,050,000,000.00
2026 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount							$ 500,000,000
Stated interest rate			5.50%				5.50%
2028 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Proceeds from private offering of debt	$ 500,000,000.0
Aggregate principal amount					$ 500,000,000
Maximum consolidated indebtedness to consolidated EBITDA						4.00
Stated interest rate			4.25%		4.25%
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding			$ 8,300,000		$ 7,500,000
Minimum \| Foreign Exchange Forward
Debt Instrument [Line Items]
Derivative amount			300,000,000
Maximum \| Foreign Exchange Forward
Debt Instrument [Line Items]
Derivative amount			400,000,000
Other Nonoperating Income (Expense) \| Foreign Exchange Forward
Debt Instrument [Line Items]
Foreign currency losses recognized			4,200,000	$ 6,400,000
Recognized gains from derivatives			(892,000)	0
Interest Expense \| Foreign Exchange Forward
Debt Instrument [Line Items]
Recognized gains from derivatives			$ 6,067,000	$ 8,917,000

EQUITY AND NONCONTROLLING INTERESTS - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Numerator:
Net income	$ 50,837	$ 55,688
Less: Net income attributable to noncontrolling interests	68	555
Net income attributable to common shareholders	$ 50,769	$ 55,133
Denominator:
Weighted-average shares outstanding—Basic (in shares)	49,189	48,458
Effect of dilutive securities:
Stock options, restricted stock units and performance share units (in shares)	777	1,004
Weighted-average shares outstanding—Diluted (in shares)	49,966	49,462

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Feb. 29, 2020	Dec. 28, 2019
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest	92.00%
Noncontrolling interest ownership percentage	8.00%
Citoxlab
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest				90.00%
Noncontrolling interest ownership percentage				10.00%
Supplier
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest				80.00%
Noncontrolling interest ownership percentage				20.00%
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.4
Restricted Stock and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.6	1.0
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contractually defined redemption value	$ 14.7
Citoxlab
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contingent consideration liability			$ 2.0
Contractually defined redemption value			$ 4.0

EQUITY AND NONCONTROLLING INTERESTS - Treasury Shares (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Equity, Class of Treasury Stock [Line Items]
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	100,000	100,000
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 23.7	$ 17.8
Authorized Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Shares repurchased during period (in shares)	0	0
Remaining authorized repurchase amount	$ 129.1

EQUITY AND NONCONTROLLING INTERESTS - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 1,637,828	$ 1,319,778
Other comprehensive loss before reclassifications	(44,311)
Amounts reclassified from accumulated other comprehensive loss	1,374
Net current period other comprehensive income (loss)	(42,937)
Income tax expense (benefit)	(2,039)	(102)
Ending balance	1,655,627	1,401,029
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(87,578)
Other comprehensive loss before reclassifications	(44,311)
Amounts reclassified from accumulated other comprehensive loss	0
Net current period other comprehensive income (loss)	(44,311)
Income tax expense (benefit)	(2,330)
Ending balance	(129,559)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(90,441)
Other comprehensive loss before reclassifications	0
Amounts reclassified from accumulated other comprehensive loss	1,374
Net current period other comprehensive income (loss)	1,374
Income tax expense (benefit)	291
Ending balance	(89,358)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(178,019)	(172,703)
Ending balance	$ (218,917)	$ (162,800)

EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 28,647	$ 18,525
Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]
Net (loss) income attributable to noncontrolling interests	(332)	85
Foreign currency translation	(544)	458
Ending balance	24,039	20,519
Citoxlab
Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]
Acquisition of noncontrolling interest	(3,732)	0
Vital River
Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]
Adjustment to Vital River redemption value	$ 0	$ 1,451

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Mar. 28, 2020	Mar. 30, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	8.30%	16.00%
Decrease in unrecognized tax benefits	$ 0.6
Unrecognized tax benefits	19.1
Decrease in unrecognized tax benefits that would impact effective tax rate	0.7
Unrecognized tax benefits that would impact effective tax rate	16.3
Accrued interest and penalties on unrecognized tax benefits	2.3
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period (up to)	$ 3.0

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Employee benefits
Service cost	$ 797	$ 630
Interest cost	2,355	2,875
Expected return on plan assets	(2,981)	(3,235)
Amortization of prior service cost (credit)	(125)	91
Amortization of net loss	1,586	489
Other adjustments	125	0
Net periodic cost	1,757	850
Other Postretirement Benefits Plan
Employee benefits
Net periodic cost	$ 0	$ 0

STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 10,960	$ 12,899
Provision for income taxes	(1,551)	(2,047)
Stock-based compensation, net of income taxes	9,409	10,852
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	2,035	1,949
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 8,925	$ 10,950

FOREIGN CURRENCY CONTRACTS - Schedule of Derivative Instruments on Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ (15,067)	$ (9,987)
Other (expense) income, net	(24,071)	6,306
Foreign Exchange Forward \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Recognized gains from derivatives	6,067	8,917
Foreign Exchange Forward \| Other Income (Expense), Net
Derivative Instruments, Gain (Loss) [Line Items]
Recognized gains from derivatives	$ (892)	$ 0

FOREIGN CURRENCY CONTRACTS - Narrative (Details) - Foreign Exchange Forward - derivative_instrument	12 Months Ended
	Dec. 28, 2019	Mar. 28, 2020
Derivative [Line Items]
Number of derivative instruments held	1	0
Derivative contract, period outstanding	1 month

FOREIGN CURRENCY CONTRACTS - Schedule of Notional and Fair Value of Foreign Currency Contracts (Details) - Foreign Exchange Forward - Not Designated as Hedging Instrument - Other current liabilities $ in Thousands	Dec. 28, 2019 USD ($)
Derivatives, Fair Value [Line Items]
Notional amount	$ 115,038
Fair value, derivative liability	$ (876)

RESTRUCTURING AND ASSET IMPAIRMENTS - Restructuring Costs by Classification on the Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 559	$ 1,549
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	476	1,416
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	83	133
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	330	400
Severance and Transition Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	247	267
Severance and Transition Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	83	133
Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	229	1,149
Asset Impairments and Other Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	229	1,149
Asset Impairments and Other Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 0	$ 0

RESTRUCTURING AND ASSET IMPAIRMENTS - Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Segment Reporting Information [Line Items]
Restructuring costs	$ 559	$ 1,549
RMS
Segment Reporting Information [Line Items]
Restructuring costs	220	301
DSA
Segment Reporting Information [Line Items]
Restructuring costs	83	13
Manufacturing
Segment Reporting Information [Line Items]
Restructuring costs	$ 256	$ 1,235

RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($)	Mar. 28, 2020	Dec. 28, 2019	Mar. 30, 2019	Dec. 29, 2018
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	$ 2,531,000	$ 6,406,000	$ 2,113,000	$ 2,921,000
Accrued Compensation
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	2,400,000		1,800,000
Severance and Transition Costs \| Other Noncurrent Liabilities
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	$ 100,000		$ 300,000

RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition Costs Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Restructuring Reserve [Roll Forward]
Beginning balance	$ 6,406	$ 2,921
Expense (excluding non-cash charges)	517	1,246
Payments / utilization	(4,243)	(2,034)
Foreign currency adjustments	(149)	(20)
Ending balance	$ 2,531	$ 2,113

LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Leases [Abstract]
Operating lease right-of-use assets, net	$ 155,568	$ 140,085
Other current liabilities	22,469	20,357
Operating lease right-of-use liabilities	133,440	116,252
Total operating lease liabilities	155,909	136,609
Finance leases - property, plant and equipment, net	30,859	32,519
Current portion of long-term debt and finance leases	2,929	2,997
Long-term debt, net and finance leases	25,879	27,530
Total finance lease liabilities	$ 28,808	$ 30,527

LEASES - Components of Operating and Finance Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Leases [Abstract]
Operating lease costs	$ 8,077	$ 7,706
Amortization of right-of-use assets	951	921
Interest on lease liabilities	340	296
Short-term lease costs	589	192
Variable lease costs	1,045	335
Sublease income	(586)	(46)
Total lease costs	$ 10,416	$ 9,404

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 28, 2020	Mar. 30, 2019
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 6,974	$ 6,533
Operating cash flows from finance leases	340	352
Finance cash flows from finance leases	1,572	838
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	25,407	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	$ 593	$ 0

LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)	Mar. 28, 2020
Weighted-average remaining lease term (in years)
Operating lease	8 years 4 months 24 days
Finance lease	12 years 8 months 15 days
Weighted-average discount rate
Operating lease	4.24%
Finance lease	4.54%

LEASES - Schedule of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 28, 2020	Dec. 28, 2019
Operating Leases, After Adoption of 842
2020 (excluding the three months ended March 28, 2020)	$ 21,347
2020	27,308
2021	23,483
2022	19,810
2023	19,168
Thereafter	76,170
Total minimum future lease payments	187,286
Less: Imputed interest	31,377
Total lease liabilities	155,909	$ 136,609
Finance Leases, After Adoption of 842
2020 (excluding the three months ended March 28, 2020)	3,063
2020	3,804
2021	3,754
2022	2,898
2023	2,146
Thereafter	22,531
Total minimum future lease payments	38,196
Less: Imputed interest	9,388
Total lease liabilities	$ 28,808	$ 30,527

LEASES - Narrative (Details) $ in Millions	Mar. 28, 2020 USD ($)
Lessor, Lease, Description [Line Items]
Future minimum lease payments for leases that have not yet commenced	$ 48
Minimum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	2 years
Maximum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	15 years

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Estimated Revenue Related to Performance Obligations (Details) $ in Thousands	Mar. 28, 2020 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 311,991
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 205,433
Performance obligations expected to be satisfied, expected timing	9 months 18 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 101,005
Performance obligations expected to be satisfied, expected timing	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 4,893
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 660
Performance obligations expected to be satisfied, expected timing	1 year
DSA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 292,872
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	195,192
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	92,180
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	4,861
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	639
Manufacturing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	19,119
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	10,241
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	8,825
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	32
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 21